AKAMIS BIO LIMITED

Company number 06001442

Date	Type	Description	View / Download
12 Apr 2024	RESOLUTIONS	Resolutions RES13 ‐ That, the requirements of the act as to approval of any liability limitation agreement (as defined in section 534 of the act) for the financial year ending 31 december 2023 in accordnace with section 536(2)(a) ofthe act be and hereby waived 04/04/2024 RES10 ‐ Resolution of allotment of securities	(1 page)
02 Apr 2024	RP04SH01	Second filing of a statement of capital following an allotment of shares on 8 October 2023 GBP 38,958.46	(6 pages)
02 Apr 2024	RP04SH01	Second filing of a statement of capital following an allotment of shares on 12 September 2023 GBP 35,492.95	(6 pages)
05 Feb 2024	CS01	Confirmation statement made on 2 February 2024 with updates	(18 pages)
18 Jan 2024	SH01	Statement of capital following an allotment of shares on 11 December 2023 GBP 39,012.86	(6 pages)
06 Nov 2023	TM01	Termination of appointment of Ezra Cohen as a director on 30 September 2023	(1 page)
10 Oct 2023	SH01	Statement of capital following an allotment of shares on 8 October 2023 GBP 38,945.76 ANNOTATION Clarification a second filed SH01 was registered on 02/04/2024.	(7 pages)
05 Oct 2023	AP01	Appointment of Lars Gredsted as a director on 30 June 2023	(2 pages)
04 Oct 2023	TM01	Termination of appointment of Paolo Paoletti as a director on 30 June 2023	(1 page)
04 Oct 2023	TM01	Termination of appointment of Mette Kristine Agger as a director on 30 June 2023	(1 page)
29 Sep 2023	SH01	Statement of capital following an allotment of shares on 12 September 2023 GBP 35,480.25 ANNOTATION Clarification a second filed SH01 was registered on 02/04/2024.	(7 pages)
29 Aug 2023	AP04	Appointment of Oakwood Corporate Secretary Limited as a secretary on 10 July 2023	(2 pages)
06 Jul 2023	AA	Group of companies' accounts made up to 31 December 2022	(54 pages)
21 Jun 2023	PSC08	Notification of a person with significant control statement	(2 pages)
20 Jun 2023	SH01	Statement of capital following an allotment of shares on 17 June 2023 GBP 255,245.05	(6 pages)
05 Jun 2023	AP01	Appointment of Dr Christopher Bowden as a director on 1 June 2023	(2 pages)
16 May 2023	PSC07	Cessation of Ip2Ipo Portfolio (Gp) Limited as a person with significant control on 1 January 2023	(1 page)
16 May 2023	PSC07	Cessation of Imperial Innovations Businesses Llp as a person with significant control on 1 January 2023	(1 page)
15 May 2023	SH01	Statement of capital following an allotment of shares on 30 April 2023 GBP 34,603.65	(6 pages)
14 Feb 2023	CS01	Confirmation statement made on 2 February 2023 with updates	(15 pages)
14 Feb 2023	SH01	Statement of capital following an allotment of shares on 31 December 2022 GBP 34,588.95	(6 pages)
03 Jan 2023	AD01	Registered office address changed from Psioxus House 4-10 the Quadrant Abingdon Science Park Abingdon OX14 3YS England to Akamis House 4-10 the Quadrant Barton Lane Abingdon Oxfordshire OX14 3YS on 3 January 2023	(1 page)
03 Jan 2023	CERTNM	Company name changed psioxus therapeutics LIMITED\certificate issued on 03/01/23 NM01 ‐ Change of name by resolution RES15 ‐ Change company name resolution on 2022-12-23	(3 pages)
02 Nov 2022	TM02	Termination of appointment of Priya Mande as a secretary on 28 October 2022	(1 page)
18 Oct 2022	RESOLUTIONS	Resolutions RES10 ‐ Resolution of allotment of securities	(1 page)